KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Barbara Botto, Carola Boccomini, Andrea Evangelista, Vittorio Ruggero Zilioli, Antonella Anastasia, Federica Cavallo, Francesco Merli, Manuela Zanni, Monica Tani, Annalisa Chiarenza, Anna Marina Liberati, Annarita Conconi, Chiara Rusconi, Alessia Bari, Ilaria Del Giudice, Gianluca Gaidano, Michele Spina, Nilla Maschio, Claudia Castellino, Delia Rota-Scalabrini, Benedetta Puccini, Annalisa Arcari, Sara Bigliardi, Giorgia Maria Elena Matta, Benedetta Bianchi, Donato Mannina, Dario Marino, Piero Galieni, Fabrizio Ciambelli, Gerardo Musuraca, Cristina Muzi, Chiara Bottelli, Elisa Genuardi, Erika Meli, Simone Ferrero, Stefano Luminari, Marco Ladetto, Giovannino Ciccone, Umberto Vitolo

Blood Adv bloodadvances.2025018732

PMID42349017
PMCID-
DOI10.1182/bloodadvances.2025018732
发表日期2026-06-25
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

Maintenance treatment in elderly patients with relapsed or refractory (R/R) follicular lymphoma (FL) remains an area of investigation. RENOIR was a multicenter, phase III, open-label randomized trial conducted by the Fondazione Italiana Linfomi (FIL) in elderly patients with R/R FL after one or two prior therapies. Patients achieving partial or complete response (PR/CR) after 4-6 cycles of standard rituximab-based chemotherapy were randomized 1:1 to maintenance with rituximab alone (R, standard arm) or rituximab plus lenalidomide (R2, experimental arm). The primary endpoint was 2-year progression-free survival (PFS) from randomization with an expected HR =0.5. A total of 152 patients (median age 71 years) were enrolled. After induction, 129 (85%) achieved an overall response (CR 58%) and were randomized to R (n=65) or R2 (n=64). At a median follow-up of 68 months, the 2-year PFS was 73% in the R2 arm and 64% in the R arm (HR 0.73, 95% CI 0.46-1.16, p=.183). An unplanned hypothesis- generating subgroup analysis showed a greater 2-year PFS benefit with R2 in patients aged <70y (HR=0.35): R2 96% vs R 69%. Two-year overall survival (OS) rates were similar (R2 80% vs R 89%; HR 1.12). Grade 3/4 adverse events were more frequent in R2, mainly neutropenia and gastrointestinal disorders. In conclusion, the primary endpoint of the study was not met and R2 maintenance did not significantly improve 2-year PFS in elderly patients with R/R FL, though a numerically benefit was observed. R2 showed a more favorable benefit/risk profile in patients <70 years whereas in older patients careful consideration of individual tolerability is warranted. Trial registration: RENOIR study (NCT02390869) clinicaltrial.gov.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。